Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072565 | 0.80 | ALDH1A1 (0.47) | ALDH1A1ALOX15TSHRKDM4ELMNA | |
| SCHEMBL4734769 | 0.75 | MEN1 (0.34) | MEN1HTTKMT2A | |
| SCHEMBL3444583 | 0.72 | ALDH1A1 (0.39) | ALDH1A1ALOX15TSHRKDM4ELMNA | |
| SCHEMBL16268194 | 0.70 | CYP1A2 (0.44) | — | |
| SCHEMBL3847571 | 0.68 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHRKDM4ELMNA | |
| SCHEMBL22075893 | 0.68 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHRKDM4ELMNA | |
| SCHEMBL21498130 | 0.68 | ALDH1A1 (0.38) | ALDH1A1ALOX15TSHRKDM4ELMNA | |
| SCHEMBL31576467 | 0.65 | GOT1 (0.32) | ALDH1A1ALOX15TSHRKDM4ELMNA | |
| SCHEMBL28696134 | 0.65 | MEN1 (0.33) | MEN1HTTKMT2A | |
| SCHEMBL21299377 | 0.64 | ALDH1A1 (0.30) | ALDH1A1ALOX15TSHRKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11286243-B2 | Ferroportin inhibitors and methods of use | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3894416-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | Global Blood Therapeutics, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123850-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286243-B2 | Ferroportin inhibitors and methods of use | SLC40A1, HAMP, SFXN1 | ALDH1A1 2334/4885ALOX15 947/4885TSHR 824/4885 |
| US-20200190045-A1 | FERROPORTIN INHIBITORS AND METHODS OF USE | SLC40A1, HAMP, TFRC | ALDH1A1 1525/4885ALOX15 383/4885TSHR 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.